Partners

Natera

Natera

Expertise Partner

Discover the latest advantages of using a personalized, tumor-informed circulating tumor DNA (ctDNA) test to design oncology clinical trials in Breast Cancer. Signatera, a breakthrough technology, can be applied in early stage and late stage cancer trials, potentially enriching for patients most likely to respond to therapy, accelerating time to trial readout, or identifying early relapsers. Dive deeper at:

www.natera.com/events/signatera-breast-cancer-event/